Table 1. Clinical Characteristics of Study Subjects.

Characteristic	RA (n = 164)			Control (n = 90)		P-Value
Demographics (mean±SD)
Age (years)		54.0±11.8	52.9±11.3		0.422
Female Sex, no. (%)		112 (68%)	56 (62%)		0.328
Caucasian, no. (%)		147 (90%)	76 (84%)		0.227
Non-smoker, no. (%)		39 (24%)	8 (9%)		0.003
Disease Activity Score (DAS28)		3.9 (2.6–4.9)	-		-
Disease Duration (years)		3 (2–18)	-		-
Cardiovascular Risk Factor
Hypertension, no. (%)		85 (52%)		35 (39%)		0.048
Systolic BP, mmHg (mean±SD)		132.8±20.2		129.1±17.5		0.133
Diastolic BP, mmHg (mean±SD)		74.81±10.89		72.74±8.82		0.185
CVD or coronary procedure, no. (%)		22 (13%)		8 (9%)		0.285
Diabetic, no. (%)		18 (11%)		4 (4%)		0.077
On NSAIDS, no. (%)		54 (33%)		36 (40%)		0.26
BMI, kg/m2 (mean±SD)		29.14±6.63		28.54±5.88		0.543
CACS (Agatston Units) (median, IQR)		2.7 (0.0–150.4)		0.0 (0.0–19.2)		0.021
RA treatment regimens
Current corticosteroid use, no. (%)	88 (54%)			-		-
Current methotrexate use, no. (%)	118 (72%)			-		-
Current antimalarial use, no. (%)	42(26%)			-		-
Current anti-TNF agent use, no. (%)	34 (21%)			-		-
Laboratory Measurements (median, IQR)
HDL (mg/dL)	43.0 (37.0–54.0)			45.0 (38.0–54.0)		0.705
LDL (mg/dL)	111.0 (88.5–135.5)			121.0 (104.0–140.0)		0.031
Homocysteine (µmol/L)	2.317 (2.083–2.477)			2.104 (1.978–2.270)		<0.001
Creatinine (mg/dL)	0.800 (0.700–0.900)			0.800 (0.700–0.900)		0.408
TNFa (pg/mL)	5.41 (2.72–11.00)			3.38 (2.35–4.67)		<0.001
IL-6 (pg/mL)	13.81 (4.41–42.36)			4.25 (1.15–18.27)		<0.001
CRP (mg/L)	4.00 (1.19–11.00)			0.55 (0.21–1.53)		<0.001
NT-BNP (pg/mL)	89.7 (28.7–232.3)			18.0 (3.2–39.0)		<0.001
hs-cTn-I (pg/mL)	1.150 (0.730–1.922)			0.770 (0.492–1.277)		<0.001

P values were determined by Wilcoxon’s rank sum test or chi-square test.